NO20015746D0 - Ny anvendelse av 1-[4-(5-cyanindol-3-yl)butyl]-4-(2- karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptablesalter - Google Patents

Ny anvendelse av 1-[4-(5-cyanindol-3-yl)butyl]-4-(2- karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptablesalter

Info

Publication number
NO20015746D0
NO20015746D0 NO20015746A NO20015746A NO20015746D0 NO 20015746 D0 NO20015746 D0 NO 20015746D0 NO 20015746 A NO20015746 A NO 20015746A NO 20015746 A NO20015746 A NO 20015746A NO 20015746 D0 NO20015746 D0 NO 20015746D0
Authority
NO
Norway
Prior art keywords
cyanindol
carbamoylbenzofuran
piperazine
butyl
acceptable salts
Prior art date
Application number
NO20015746A
Other languages
English (en)
Other versions
NO322120B1 (no
NO20015746L (no
Inventor
Gerd Bartoszyk
Christoph Seyfried
Christoph Van Amsterdam
Henning Boettcher
Ewen Sedman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20015746(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20015746D0 publication Critical patent/NO20015746D0/no
Publication of NO20015746L publication Critical patent/NO20015746L/no
Publication of NO322120B1 publication Critical patent/NO322120B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20015746A 1999-05-27 2001-11-26 Anvendelse av 1-[4-(5-cyanindol-3-yl)butyl]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av angstforstyrrelser av undertype NO322120B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27
PCT/EP2000/004376 WO2000072832A2 (en) 1999-05-27 2000-05-16 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts

Publications (3)

Publication Number Publication Date
NO20015746D0 true NO20015746D0 (no) 2001-11-26
NO20015746L NO20015746L (no) 2001-11-26
NO322120B1 NO322120B1 (no) 2006-08-14

Family

ID=8238153

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20015746A NO322120B1 (no) 1999-05-27 2001-11-26 Anvendelse av 1-[4-(5-cyanindol-3-yl)butyl]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av angstforstyrrelser av undertype
NO20061562A NO324230B1 (no) 1999-05-27 2006-04-06 Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av bipolare forstyrrelser og mani

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20061562A NO324230B1 (no) 1999-05-27 2006-04-06 Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av bipolare forstyrrelser og mani

Country Status (31)

Country Link
US (4) US6900212B1 (no)
EP (3) EP1410800B1 (no)
JP (2) JP4884588B2 (no)
KR (1) KR100683367B1 (no)
CN (3) CN1679577A (no)
AR (1) AR024112A1 (no)
AT (3) ATE438399T1 (no)
AU (1) AU771778B2 (no)
BR (1) BR0010948A (no)
CA (3) CA2615271C (no)
CY (2) CY1105750T1 (no)
CZ (1) CZ295623B6 (no)
DE (3) DE60042710D1 (no)
DK (3) DK1185272T3 (no)
ES (3) ES2219342T3 (no)
HK (1) HK1048444B (no)
HU (1) HU229059B1 (no)
IL (2) IL146707A0 (no)
MX (1) MXPA01012172A (no)
MY (1) MY135627A (no)
NO (2) NO322120B1 (no)
PL (3) PL199516B1 (no)
PT (3) PT1410800E (no)
RU (1) RU2237477C2 (no)
SI (2) SI1185272T1 (no)
SK (1) SK287851B6 (no)
TR (1) TR200103361T2 (no)
TW (1) TW518218B (no)
UA (1) UA74337C2 (no)
WO (1) WO2000072832A2 (no)
ZA (1) ZA200110485B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
WO2004082686A2 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
BRPI0712796A2 (pt) 2006-05-30 2012-10-02 Astrazeneca Ab composto, métodos para produzir uma inibição da atividade de dgat1 em um animal de sangue quente, para tratar a diabete melito e/ou a obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para um composto
EA201001015A1 (ru) 2007-12-20 2011-02-28 Астразенека Аб Карбамоиловые соединения в качестве ингибиторов dgat1 190
UY32716A (es) 2009-06-19 2011-01-31 Astrazeneca Ab Compuestos de pirazina carboxamida útiles para el tratamiento de diabetes y obesidad
CN102781436B (zh) 2009-11-06 2014-01-08 爱思开生物制药株式会社 纤维肌痛综合征的治疗方法
JP5836280B2 (ja) 2009-11-06 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012131706A1 (en) 2011-03-20 2012-10-04 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
WO2013185209A1 (en) 2012-06-13 2013-12-19 Apotex Technologies Inc. Forms of vilazodone and processes for the preparation thereof
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
CA2898619C (en) 2013-01-22 2021-10-19 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
IL296380A (en) * 2015-05-22 2022-11-01 Vistagen Therapeutics Inc Medicinal uses for l–4–chlorokynurenine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612813A3 (en) * 2001-09-11 2009-12-09 JTEKT Corporation Magnetizing device with pole array, and magnetizing method
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
ES2330774T3 (es) 2009-12-15
IL146707A0 (en) 2002-07-25
HK1048444B (zh) 2005-12-09
WO2000072832A2 (en) 2000-12-07
DK1410800T3 (da) 2006-12-27
PL352373A1 (en) 2003-08-25
CN1361692A (zh) 2002-07-31
HUP0201275A3 (en) 2004-04-28
DE60030338D1 (de) 2006-10-05
ATE337008T1 (de) 2006-09-15
CZ295623B6 (cs) 2005-09-14
SI1410800T1 (sl) 2007-02-28
HU229059B1 (en) 2013-07-29
CA2372668A1 (en) 2000-12-07
DE60042710D1 (de) 2009-09-17
DE60030338T2 (de) 2007-08-16
KR100683367B1 (ko) 2007-02-15
US7642261B2 (en) 2010-01-05
JP4884588B2 (ja) 2012-02-29
CN1198618C (zh) 2005-04-27
NO322120B1 (no) 2006-08-14
CY1105750T1 (el) 2010-12-22
UA74337C2 (uk) 2005-12-15
HUP0201275A2 (en) 2002-08-28
ZA200110485B (en) 2003-06-30
CA2615271A1 (en) 2000-12-07
EP1736158A3 (en) 2007-01-03
CA2615271C (en) 2011-02-15
CY1109472T1 (el) 2012-05-23
EP1410800B1 (en) 2006-08-23
HK1048444A1 (en) 2003-04-04
AR024112A1 (es) 2002-09-04
EP1736158A2 (en) 2006-12-27
RU2237477C2 (ru) 2004-10-10
WO2000072832A3 (en) 2001-12-20
PT1410800E (pt) 2007-01-31
SI1185272T1 (en) 2004-12-31
AU771778B2 (en) 2004-04-01
PT1736158E (pt) 2009-11-11
PL200490B1 (pl) 2009-01-30
MXPA01012172A (es) 2002-07-22
PT1185272E (pt) 2004-08-31
CA2372668C (en) 2009-11-03
SK287851B6 (sk) 2012-01-04
TW518218B (en) 2003-01-21
JP2011148799A (ja) 2011-08-04
PL199650B1 (pl) 2008-10-31
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
ATE438399T1 (de) 2009-08-15
ES2271707T3 (es) 2007-04-16
NO324230B1 (no) 2007-09-10
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
SK16462001A3 (sk) 2002-02-05
DK1185272T3 (da) 2004-08-09
JP2003500441A (ja) 2003-01-07
US20100063062A1 (en) 2010-03-11
DE60009697D1 (de) 2004-05-13
EP1410800A1 (en) 2004-04-21
MY135627A (en) 2008-05-30
US7371756B2 (en) 2008-05-13
BR0010948A (pt) 2002-04-23
AU5066300A (en) 2000-12-18
ATE263564T1 (de) 2004-04-15
NO20061562L (no) 2001-11-26
NO20015746L (no) 2001-11-26
EP1185272B1 (en) 2004-04-07
DK1736158T3 (da) 2009-11-02
CZ20014226A3 (cs) 2002-03-13
EP1736158B1 (en) 2009-08-05
CN101869565A (zh) 2010-10-27
US20080119484A1 (en) 2008-05-22
TR200103361T2 (tr) 2002-05-21
CA2694866A1 (en) 2000-12-07
CN1679577A (zh) 2005-10-12
IL146707A (en) 2007-06-03
DE60009697T2 (de) 2005-04-14
PL199516B1 (pl) 2008-09-30
KR20020008847A (ko) 2002-01-31

Similar Documents

Publication Publication Date Title
NO20015746D0 (no) Ny anvendelse av 1-[4-(5-cyanindol-3-yl)butyl]-4-(2- karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptablesalter
EE05454B1 (et) 1-[4-(5-tsanoindool-3-l)butl]-4-(2-karbamolbensofuraan-5-l)piperasiinvesinikkloriidi polmorfsed vormid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
NO20000115L (no) Gastrokinetiske monocykliske benzamidler av 3- eller 4- substituerte 4-(aminometyl)-piperidinderivater
NO20023787D0 (no) Piperazin- og piperidinderivater
EE200100498A (et) 1,4-asendatud piperasiin-, 1,4-asendatud piperidiin- ja 1-asendatud 4-alkülidenüülpiperidiinühendidning nende raviotstarbeline kasutamine
NO984380D0 (no) Nye piperazin og piperidin forbindelser
DK1283838T3 (da) Piperazin- og piperidinforbindelser
SG127737A1 (en) Piperidine and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
DK1055658T3 (da) Fremstilling af cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphtalen-1-yl)phenoxy]ethyl-pyrrolidin
HUP9800511A3 (en) Phosphorylized derivatives of 4-{4-[4-(hydroxy-diphenyl)-1-pipe
DE60204791D1 (de) Synthese von 4-(piperidyl) (2-pyridyl)methanon-(e)-o-methyloxim und seinen salzen
EE200000638A (et) 1-(6-kloronaft-2-üülsulfonüül)-4-[4-(4-püridüül)bensoüül]-piperasiini vähendatud osakesesuurusega vorm
NO20031698D0 (no) Krystallformer av 1-(6-klor-5-(trifluormetyl)-2- pyridinyl)piperazin-hydroklorid
DK0888336T3 (da) Nye substituerede N-methyl-N-(4-(4-(1H-benzimidazol-2-yl-amino)-piperidin-1-yl)-1-(aryl)butyl)benzamider til behandling af allergisygdomme
DK0848707T3 (da) Derivater af 4-(cycloalkyl)piperidiner og 4-(cycloalkyl)piperidiner, deres fremstilling og terapeutiske anvendelse
AU2002359274A1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts
AU4595100A (en) ((e),3(r))-enantiomer of 4-(3-chloro -4-cyanophenyl) -1-(p- methylsulphonyl -phenylsulphonyl) -2-trifluoromethylbut -trans-3-en-ol
NO995894D0 (no) 2-(4-(4-(4,5-diklor-2-metylimidazol-1-yl)butyl)-1-piperazinyl)-5-fluorpyrimidin, fremstilling og terapeutisk anvendelse
HUP0401645A3 (en) Alpha crystal form of 4-(4-methyl-piperazine-1-yl-methyl)-n-[4-methyl-3-(4-pyridine-3-yl)-pyrimidine-2-yl-amino]-phenyl)-benzamide monomethanesulfonate
IL122975A0 (en) Use of 1-[6-chloro-5- (trifluoromethyl)-2-pyridinyl] piperazine

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees